Peres Jepchirchir Provisionally Suspended After Positive EPO Test, Sydney Marathon Victory Under Scrutiny
core_answer: केन्या की ओलंपिक और विश्व मैराथन चैंपियन पेरिस जेपचिरचिर को 23 अक्टूबर 2026 को AIU ने अस्थायी रूप से निलंबित किया। सिडनी मैराथन से पहले लिए गए नमूने में प्रतिबंधित पदार्थ EPO का प्रतिकूल विश्लेषणात्मक परिणाम मिला है। अंतिम डोपिंग उल्लंघन अभी स्थापित नहीं हुआ है।
key_facts: नमूना सिडनी मैराथन से पहले केन्या में प्रतियोगिता से बाहर लिया गया था।; जेपचिरचिर ने 30 अगस्त 2026 को सिडनी मैराथन 2:18:31 में जीती।; दूसरे स्थान पर रहीं आइरीन चेपेट चेप्टाई तीन मिनट से अधिक पीछे थीं।; जेपचिरचिर ने 2021 टोक्यो ओलंपिक और सितंबर 2025 विश्व चैंपियनशिप में मैराथन स्वर्ण जीता।; EPO लाल रक्त कोशिकाओं का उत्पादन बढ़ाता है और सहनशक्ति प्रदर्शन को प्रभावित कर सकता है।
source_attribution: Athletics Integrity Unit (AIU) आधिकारिक घोषणा, 23 अक्टूबर 2026; TCS Sydney Marathon आधिकारिक बयान, 23 अक्टूबर 2026; Reuters, 23 अक्टूबर 2026।
related_qa: question: पेरिस जेपचिरचिर को क्यों निलंबित किया गया?, answer: सिडनी मैराथन से पहले केन्या में लिए गए उनके नमूने में प्रतिबंधित पदार्थ EPO का प्रतिकूल विश्लेषणात्मक परिणाम मिला।; question: क्या जेपचिरचिर की सिडनी मैराथन जीत रद्द हो गई है?, answer: नहीं, अभी कोई अंतिम अयोग्यता या परिणाम रद्द करने का निर्णय घोषित नहीं हुआ है।; question: EPO का खिलाड़ियों के प्रदर्शन पर क्या प्रभाव पड़ता है?, answer: EPO लाल रक्त कोशिकाओं का उत्पादन बढ़ाकर रक्त की ऑक्सीजन वहन करने की क्षमता बढ़ा सकता है, जिससे सहनशक्ति प्रदर्शन प्रभावित हो सकता है।
Peres Jepchirchir's EPO Finding Puts Sydney Marathon Victory Under Scrutiny
When Peres Jepchirchir crossed the finish line in front of the Sydney Opera House on August 30, 2026, she had delivered another commanding performance in an already distinguished marathon career. The Kenyan runner completed the women's race in 2:18:31, finishing more than three minutes ahead of compatriot Irine Cheptai. Sydney had become the seventh Abbott World Marathon Major in 2026, making the victory another significant addition to Jepchirchir's international record.
However, the Athletics Integrity Unit (AIU) announced on October 23, 2026, that Jepchirchir had been provisionally suspended after an out-of-competition sample collected in Kenya before the Sydney race returned an adverse analytical finding for erythropoietin (EPO).
The distinction between an adverse analytical finding and a final anti-doping violation is essential. A provisional suspension is not a final determination of guilt. The athlete is entitled to due process, and the relevant anti-doping procedures must be completed before a final conclusion is reached. Nevertheless, the case has raised important questions about the reliability of a major marathon result and the wider integrity of women's distance running.
An Olympic and World Champion
Jepchirchir established herself among the leading marathon runners through a series of major international performances. She won the women's marathon at the Tokyo Olympic Games in 2026, officially known as Tokyo 2026, before returning to the Japanese capital in September 2026 to claim the World Athletics Championships marathon title.
Her achievements also extend to the half-marathon. She broke the women's half-marathon world record in 2026 and improved it three times during 2026. On the marathon circuit, she won the New York City Marathon in 2026, the Boston Marathon in 2026 and the London Marathon in 2026. Her Sydney victory in 2026 added another major title to that record.
These results explain why the AIU announcement has attracted such considerable attention. Jepchirchir was an established international champion rather than an emerging runner whose reputation depended on a single performance. The implications of the investigation therefore extend beyond the Sydney result.
Why EPO Matters in Endurance Sport
Erythropoietin is a naturally occurring hormone produced primarily by the kidneys. It stimulates the bone marrow to produce red blood cells. These cells contain haemoglobin, which transports oxygen from the lungs to muscles and other tissues.
In marathon running, oxygen delivery plays an important role in sustaining prolonged physical effort. Artificial EPO use can increase red blood cell production and potentially improve the blood's oxygen-carrying capacity. This is why EPO is prohibited in competitive sport.
Its misuse also presents serious health risks. An excessive increase in red blood cells can make blood more viscous, potentially increasing the risk of blood clots, strokes and cardiovascular complications.
Detecting EPO requires specialised laboratory testing. The substance's detectability depends on the circumstances and testing methods, which makes out-of-competition testing particularly important. In Jepchirchir's case, the sample was collected in Kenya before her Sydney victory rather than during the race itself.
The Sydney Result and Its Wider Implications
Jepchirchir's winning time of 2:18:31 placed her more than three minutes ahead of second-placed Irine Cheptai. That margin made the Kenyan runner's performance one of the defining results of the women's race.
The investigation now places additional attention on the athletes who finished behind her. Cheptai and the other competitors completed the race under the published results, but any eventual consequences will depend on the outcome of the anti-doping proceedings and the applicable rules.
No final decision has yet been announced that removes Jepchirchir's Sydney victory. It would therefore be premature to describe Cheptai as the official winner or to claim that the results have already been amended.
For elite marathon runners, a podium position represents years of training, travel, coaching and financial investment. The integrity of the results matters to every athlete, particularly those whose final positions could be affected by a later disciplinary decision.
Sydney Organisers Reaffirm Commitment to Clean Sport
The Sydney Marathon organisers issued a statement on October 23, expressing disappointment over the AIU announcement. They also emphasised that Jepchirchir was entitled to due process and said they would make no further comment until the proceedings had concluded.

The organisers reiterated their commitment to clean sport and explained that they had invested in increased out-of-competition testing in partnership with the AIU and other Abbott World Marathon Majors events.
They also highlighted a significant circuit rule: athletes receiving a ban of three months or longer for a doping offence can face a lifetime ban from all eight World Marathon Majors. This consequence would depend on a final finding and the applicable disciplinary provisions; it does not automatically apply at the provisional suspension stage.
Kenya's Distance-Running Record Under Scrutiny
Kenya remains one of the most influential countries in international distance running. Its athletes have consistently won Olympic, world championship and major marathon titles. However, a growing number of anti-doping cases have raised questions about the effectiveness of testing and athlete support systems.
Reports published in October 2026 indicated that more than 140 Kenyan athletes had been sanctioned since the AIU was established in 2026. Each case has its own circumstances, but the number highlights the importance of stronger testing, transparent investigations and effective athlete education.
In 2026, Kenyan marathon world record holder Ruth Chepngetich received a three-year ban following anti-doping rule violations involving hydrochlorothiazide. Her world record of 2:09:56 remained on the books because it had been established before the relevant sample date.
Jepchirchir's case involves a different substance and must be assessed independently. It should not be used to cast suspicion on every Kenyan distance runner. Equally, the country's exceptional running tradition makes effective anti-doping safeguards particularly important for athletes who compete cleanly.
What Happens Next?
A provisional suspension prevents an athlete from competing while the case proceeds, but it does not represent a final sanction. The athlete has rights under the anti-doping rules, including the opportunity to challenge relevant evidence and use the applicable sample-analysis procedures.
Jepchirchir's agent, Gianni Demadonna, said on October 23 that he felt terrible about the situation and believed athletes who use performance-enhancing drugs should be disqualified. His statement represents the agent's reaction and should not be treated as an admission by Jepchirchir.
The outstanding questions concern the final laboratory and disciplinary findings, the athlete's response and the possible consequences for affected competition results. Until the process is complete, the Sydney result remains subject to the established record and applicable rules.
Jepchirchir's Olympic gold, 2026 world title and major marathon victories remain important parts of her career record. The current investigation, however, places the integrity of her latest major victory under scrutiny. The coming months will test whether international marathon organisers and anti-doping authorities can provide a transparent, timely and fair resolution that protects both the rights of the athlete and the work of every clean competitor.
